Metabolic and Kinetic analyses of influenza production in perfusion HEK293 cell culture

BMC Biotechnology

Volumn 11, Issue , 2011, Pages

  Petiot, Emma ^a,b   Jacob, Danielle ^a   Lanthier, Stephane ^a   Lohr, Verena ^c   Ansorge, Sven ^a   Kamen, Amine A ^a,b  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b ÉCOLE POLYTECHNIQUE DE MONTRÉAL   (Canada)

^c MAX PLANCK INSTITUTE FOR DYNAMICS OF COMPLEX TECHNICAL SYSTEMS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CELL CULTURE; CELL DEATH; COST EFFECTIVENESS; KINETICS; METABOLISM; PHYSIOLOGY; SUBSTRATES; VACCINES; VIRUSES;

COST-EFFECTIVE MANUFACTURING; CULTURE ENVIRONMENTS; INDUSTRIAL MANUFACTURING; KEY SUCCESS FACTORS; PERFUSION CULTURES; PHYSIOLOGICAL INDICATORS; SHORT RESPONSE TIME; VOLUMETRIC PRODUCTION;

BATCH CELL CULTURE;

AMINO ACID; INFLUENZA VACCINE;

AMINO ACID METABOLISM; APOPTOSIS; ARTICLE; BACTERIUM CULTURE; BIOREACTOR; CELL CULTURE; CELL DENSITY; CELL METABOLISM; CELL VIABILITY; GLYCOLYSIS; INFLUENZA VIRUS; PERFUSION; VACCINE PRODUCTION; VIRUS REPLICATION; ANIMAL; CELL LINE; CELL PROLIFERATION; CELL STRAIN HEK293; CELL SURVIVAL; CHEMISTRY; CULTURE TECHNIQUE; DOG; HUMAN; INFLUENZA VIRUS A H1N1; KINETICS; METABOLISM; METHODOLOGY; TEMPERATURE; VIRION; VIROLOGY; VIRUS CULTURE;

ORTHOMYXOVIRIDAE;

AMINO ACIDS; ANIMALS; APOPTOSIS; BIOREACTORS; CELL CULTURE TECHNIQUES; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; DOGS; GLYCOLYSIS; HEK293 CELLS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; KINETICS; PERFUSION; TEMPERATURE; VIRION; VIRUS CULTIVATION;

EID: 80052145378     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-11-84     Document Type: Article

References (50)

1. Onions D, Egan W, Jarrett R, Novicki D, Gregersen J-P. Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals 2010, 38(5):544-551. 10.1016/j.biologicals.2010.04.003, 20537553.
2. Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16(9-10):960-968.
3. Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Review of Vaccines 2009, 8(5):607-618. 10.1586/erv.09.19, 19397417.
4. Genzel Y, Fischer M, Reichl U. Serum-free influenza virus production avoiding washing steps and medium exchange in large-scale microcarrier culture. Vaccine 2006, 24:3261-3272. 10.1016/j.vaccine.2006.01.019, 16472544.
5. Genzel Y, Reichl U. Continuous cell lines as a production system for influenza vaccines. Expert Review of Vaccines 2009, 8(12):1681-1692. 10.1586/erv.09.128, 19943763.
6. Doroshenko A, Halperin SA. Trivalent MDCK cell culture-derived influenza vaccine Optaflu® (Novartis Vaccines). Expert Review of Vaccines 2009, 8(6):679-688. 10.1586/erv.09.31, 19485748.
7. Genzel Y, Behrendt I, Konig S, Sann H, Reichl U. Metabolism of MDCK cells during cell growth and influenza virus production in large-scale microcarrier culture. Vaccine 2004, 22(17-18):2202-2208. 10.1016/j.vaccine.2003.11.041, 15149778.
8. Lohr V, Genzel Y, Behrendt I, Scharfenberg K, Reichl U. A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor. Vaccine 2010, 28(38):6256-6264. 10.1016/j.vaccine.2010.07.004, 20638458.
9. Lohr V, Rath A, Genzel Y, Jordan I, Sandig V, Reichl U. New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: Studies on growth, metabolism and virus propagation. Vaccine 2009, 27(36):4975-4982. 10.1016/j.vaccine.2009.05.083, 19531390.
10. Pau M, Ophorst C, Koldijk M, Schouten G, Mehtali M, Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 2001, 19(17-19):2716-2721. 10.1016/S0264-410X(00)00508-9, 11257414.
11. Mehtali M. Avian cell lines derived from primordial germ cells useful for the production of substances of interest. 2007,
12. Le Ru A, Jacob D, Transfiguracion J, Ansorge S, Henry O, Kamen AA. Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing. Vaccine 2010, 28(21):3661-3671. 10.1016/j.vaccine.2010.03.029, 20347632.
13. Garnier A, Côté J, Nadeau I, Kamen A, Massie B. Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells. Cytotechnology 1994, 15(1):145-155. 10.1007/BF00762389, 7765926.
14. Nadeau I, Kamen A. Production of adenovirus vector for gene therapy. Biotechnology Advances 2003, 20(7-8):475-489. 10.1016/S0734-9750(02)00030-7, 14550017.
15. Nadeau I, Jacob D, Perrier M, Kamen A. 293SF Metabolic Flux Analysis during Cell Growth and Infection with an Adenoviral Vector. Biotechnology Progress 2000, 16(5):872-884. 10.1021/bp000098l, 11027184.
16. Lee YY, Yap MGS, Hu WS, Wong KTK. Low-Glutamine Fed-Batch Cultures of 293-HEK Serum-Free Suspension Cells for Adenovirus Production. Biotechnology Progress 2003, 19(2):501-509. 10.1021/bp025638o, 12675594.
17. Henry O, Dormond E, Perrier M, Kamen A. Insights into adenoviral vector production kinetics in acoustic filter-based perfusion cultures. Biotechnology and Bioengineering 2004, 86(7):765-774. 10.1002/bit.20074, 15162452.
18. Arden N, Betenbaugh MJ. Life and death in mammalian cell culture: strategies for apoptosis inhibition. Trends in Biotechnology 2004, 22(4):174-180. 10.1016/j.tibtech.2004.02.004, 15038922.
19. Mercille S, Massie B. Induction of apoptosis in nutrient-deprived cultures of hybridoma and myeloma cells. Biotechnology and Bioengineering 1994, 44(9):1140-1154. 10.1002/bit.260440916, 18623032.
20. Majors BS, Betenbaugh MJ, Chiang GG. Links between metabolism and apoptosis in mammalian cells: Applications for anti-apoptosis engineering. Metabolic Engineering 2007, 9(4):317-326. 10.1016/j.ymben.2007.05.003, 17611135.
21. Henry O, Jolicoeur M, Kamen A. Unraveling the metabolism of HEK-293 cells using lactate isotopomer analysis. Bioprocess and Biosystems Engineering 2011, 34(3):263-273. 10.1007/s00449-010-0468-9, 20848294.
22. Siegwart P, Côté J, Male K, Luong JHT, Perrier M, Kamen A. Adaptive Control at Low Glucose Concentration of HEK-293 Cell Serum-Free Cultures. Biotechnology Progress 1999, 15(4):608-616. 10.1021/bp990077v, 10441351.
23. Lee YY, Wong KTK, Nissom PM, Wong DCF, Yap MGS. Transcriptional profiling of batch and fed-batch protein-free 293-HEK cultures. Metabolic Engineering 2007, 9(1):52-67. 10.1016/j.ymben.2006.08.006, 17097906.
24. Nadeau I, Gilbert PA, Jacob D, Perrier M, Kamen A. Low-protein medium affects the 293SF central metabolism during growth and infection with adenovirus. Biotechnology and Bioengineering 2002, 77(1):91-104. 10.1002/bit.10128, 11745177.
25. Wahl A, Sidorenko Y, Dauner M, Genzel Y, Reichl U. Metabolic flux model for an anchorage-dependent MDCK cell line: Characteristic growth phases and minimum substrate consumption flux distribution. Biotechnology and Bioengineering 2008, 101(1):135-152. 10.1002/bit.21873, 18646224.
26. Petiot E, Guedon E, Blanchard F, Gény C, Pinton H, Marc A. Kinetic characterization of vero cell metabolism in a serum-free batch culture process. Biotechnology and Bioengineering 2010, 107(1):143-153. 10.1002/bit.22783, 20506276.
27. Cruz HJ, Freitas CM, Alves PM, Moreira JL, Carrondo MJT. Effects of ammonia and lactate on growth, metabolism, and productivity of BHK cells. Enzyme and Microbial Technology 2000, 27(1-2):43-52. 10.1016/S0141-0229(00)00151-4, 10862901.
28. Nadeau I, Garnier A, Côté J, Massie B, Chavarie C, Kamen A. Improvement of recombinant protein production with the human adenovirus/293S expression system using fed-batch strategies. Biotechnology and Bioengineering 1996, 51(6):613-623.
29. Hassell T, Gleave S, Butler M. Growth inhibition in animal cell culture. Applied Biochemistry and Biotechnology 1991, 30(1):29-41. 10.1007/BF02922022, 1952924.
30. Wentz D, Schügerl K. Influence of lactate, ammonia, and osmotic stress on adherent and suspension BHK cells. Enzyme and Microbial Technology 1992, 14(1):68-75. 10.1016/0141-0229(92)90029-N, 1367812.
31. Nadeau I, Sabatié J, Koehl M, Perrier M, Kamen A. Human 293 cell metabolism in low glutamine-supplied culture: Interpretation of metabolic changes through metabolic flux analysis. Metabolic Engineering 2000, 2(4):277-292. 10.1006/mben.2000.0152, 11120640.
32. Schmid G, Wilke CR, Blanch HW. Continuous hybridoma suspension cultures with and without cell retention: kinetics of growth, metabolism and product formation. Journal of Biotechnology 1992, 22(1-2):31-40. 10.1016/0168-1656(92)90130-2, 1367816.
33. Drews M, Doverskog M, Öhman L, Chapman BE, Jacobsson U, Kuchel PW, Häggström L. Pathways of glutamine metabolism in Spodoptera frugiperda (Sf9) insect cells: evidence for the presence of the nitrogen assimilation system, and a metabolic switch by 1H/15N NMR. Journal of Biotechnology 2000, 78(1):23-37. 10.1016/S0168-1656(99)00231-X, 10702908.
34. Schulze-Horsel J, Schulze M, Agalaridis G, Genzel Y, Reichl U. Infection dynamics and virus-induced apoptosis in cell culture-based influenza vaccine production -- Flow cytometry and mathematical modeling. Vaccine 2009, 27(20):2712-2722. 10.1016/j.vaccine.2009.02.027, 19428884.
35. Julkunen I, Sareneva T, Pirhonen J, Ronni T, Melén K, Matikainen S. Molecular pathogenesis of influenza A virus infection and virus-induced regulation of cytokine gene expression. Cytokine & Growth Factor Reviews 2001, 12(2-3):171-180. 10.1016/S1359-6101(00)00026-5, 21892805.
36. Morris S, Price G, Barnett J, Hiscox S, Smith H, Sweet C. Role of neuraminidase in influenza virus-induced apoptosis. J Gen Virol 1999, 80(1):137-146.
37. Ludwig S, Pleschka S, Planz O, Wolff T. Ringing the alarm bells: signalling and apoptosis in influenza virus infected cells. Cellular Microbiology 2006, 8(3):375-386. 10.1111/j.1462-5822.2005.00678.x, 16469051.
38. Genzel Y, Olmer R, Schafer B, Reichl U. Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media. Vaccine 2006, 24:6074-6087. 10.1016/j.vaccine.2006.05.023, 16781022.
39. Ritter J, Wahl A, Freund S, Genzel Y, Reichl U. Metabolic effects of influenza virus infection in cultured animal cells: Intra- and extracellular metabolite profiling. BMC Systems Biology 2010, 4(1):61. 10.1186/1752-0509-4-61, 2890500, 20465796.
40. Sidorenko Y, Reichl U. Structured model of influenza virus replication in MDCK cells. Biotech Bioeng 2004, 88(1):1-14.
41. Sidorenko Y, Schulze-Horsel J, Voigt A, Reichl U, Kienle A. Stochastic population balance modeling of influenza virus replication in vaccine production processes. Chemical Engineering Science 2008, 63(1):157-169.
42. Rimmelzwaan GF, Baars M, Claas ECJ, Osterhaus ADME. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. Journal of Virological Methods 1998, 74(1):57-66. 10.1016/S0166-0934(98)00071-8, 9763129.
43. Massin P, Kuntz-Simon G, Barbezange C, Deblanc C, Oger A, Marquet-Blouin E, Bougeard S, van der Werf S, Jestin V. Temperature sensitivity on growth and/or replication of H1N1, H1N2 and H3N2 influenza A viruses isolated from pigs and birds in mammalian cells. Veterinary Microbiology 2010, 142(3-4):232-241. 10.1016/j.vetmic.2009.10.012, 19926410.
44. Scholtissek C. Stability of infectious influenza A viruses at low pH and at elevated temperature. Vaccine 1985, 3(3):215-218. 10.1016/0264-410X(85)90109-4, 4060851.
45. Liu J, Shi X, Schwartz R, Kemble G. Use of MDCK cells for production of live attenuated influenza vaccine. Vaccine 2009, 27(46):6460-6463. 10.1016/j.vaccine.2009.06.024, 19559113.
46. Côté J, Garnier A, Massie B, Kamen A. Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3F6 cells. Biotechnology and Bioengineering 1998, 59(5):567-575. 10.1002/(SICI)1097-0290(19980905)59:5<567::AID-BIT6>3.0.CO;2-8, 10099373.
47. Ansorge S, Lanthier S, Transfiguracion J, Henry O, Kamen A. Monitoring lentiviral vector production kinetics using online permittivity measurements. Biochemical Engineering Journal 2011, 54(1):16-25.
48. Boogers I, Plugge W, Stokkermans YQ, Duchateau ALL. Ultra-performance liquid chromatographic analysis of amino acids in protein hydrolysates using an automated pre-column derivatisation method. Journal of Chromatography A 2008, 1189(1-2):406-409. 10.1016/j.chroma.2007.11.052, 18070624.
49. Genzel Y, Reichl U. Vaccine Production, in Animal cell biotechnology: Methods and protocol R. Pörtner Editor 2007, 457-473. Humana Press.
50. Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn-Schmiedeberg's Archives of Pharmacology 1931, 162(4):480-483.